In the News
Shelby Trieu
EDSA Announces 2025 Catalyst Award Honorees, ...

Congratulations to Project PROTECT, recently honored with the 2025 EDSA Catalyst Award for Outstanding Industry Collaboration from the End Drug Shortages Alliance. This award honors a multi-stakeholder partnership that has measurably improved drug access and strengthened supply resilience through cooperation, transparency, and innovation.

This award is especially meaningful because it reflects what Project PROTECT was built on from the very beginning: collaboration, ingenuity, and a shared commitment to protecting patients from essential medicine shortages. Together, Angels for Change, STAQ Pharma, and the Children’s Hospital Association designed and launched a model that brings hospitals, advocacy groups, manufacturers, and supply chain experts around one table to strengthen the stability of the drug supply chain. 

EDSA Announces 2025 Catalyst Award Honorees, Celebrating ‘Progress Through Partnership’ in Strengthening Drug Supply Resilience
In the News
Shelby Trieu
EDSA Advances Shared Mission to End Drug ...

The End Drug Shortages Alliance (EDSA), co-founded by Angels for Change and Vizient, has grown to more than 100 members across the healthcare supply chain. The article highlights how this expanding organization is advancing transparency, data-sharing and coordinated action to strengthen access to essential medicines. Recent progress includes a pilot with children’s hospitals and distributors focused on improving visibility for critical pediatric oncology drugs. The alliance’s continued growth reflects a shared commitment to building a more resilient, patient-centered supply chain.

EDSA Advances Shared Mission to End Drug Shortages with 100+ Members
A4C News
Shelby Trieu
2024 Annual Report
2024 Annual Report
In the News
Shelby Trieu
A4C Statement Featured in Congressional Hearing

Angels for Change Statement Included in Congressional Hearing on Strengthening the U.S. Health Care Supply Chain

Last month, the House Energy & Commerce Health Subcommittee held a critical hearing titled: “Made in America: Strengthening Domestic Manufacturing and Our Health Care Supply Chain.”

Angels for Change submitted a formal statement for the record—bringing the voice of the patient directly to policymakers.

A4C Statement Featured in Congressional Hearing
In the News
Laura Bray
Bipartisan MAPS Act Introduced to Congress

New Legislation Takes Aim at Drug Shortages—Angels for Change Recognized in MAPS Act Launch

Angels for Change is officially recognized in the introduction of the bipartisan Mapping America’s Pharmaceutical Supply (MAPS) Act, a groundbreaking bill introduced by Representatives Doris Matsui (D-CA) and Dan Crenshaw (R-TX). This legislation directly addresses vulnerabilities in the drug supply chain by requiring greater transparency, mapping critical drug components, and identifying potential risks before they impact patient care

Bipartisan MAPS Act Introduced to Congress

A4C News

, ,

Press Release: Summit One 2021

, ,
Press Release: Summit One 2021

Angels for Change, whose mission is to drive change of the life-saving drug shortage crisis through advocacy and awareness, will be hosting our second virtual summit focused on the Pediatric Oncology Drug Supply Chain on May 14, 2021 from 11:00 am to 2:30 pm EST. 

, ,

No Child Left Behind

, ,
No Child Left Behind

Cancer. A diagnosis no doctor wants to deliver, and no patient wants to hear. As devastating as the diagnosis is for an adult, it’s infinitely more tragic and terrifying when the patient is your child. Yet nearly 12,000 American parents hear that nightmare diagnosis every year. I was one of them. 

,

Industry Insights

,
Industry Insights

Every day clinicians wonder if they will have the necessary medicines to treat the patients they serve, which include pediatric cancer patients. Far too often, an oncologist has to treat a pediatric cancer patient with a therapy that is not optimal. As a parent, how would you like to hear that your child has cancer, but the best drug to treat your child is not available and that a suboptimal treatment must be administered? —Martin Van Trieste